avelox 400 mg/250 ml infusionsvätska, lösning
omnia läkemedel ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
avalox 400 mg/250 ml infusionsvätska, lösning
orifarm ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
avelox 400 mg/250 ml infusionsvätska, lösning
medartuum ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
avelox 400 mg/250 ml infusionsvätska, lösning
medartuum ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
avelox 400 mg/250 ml infusionsvätska, lösning
pharmachim ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
actira 400 mg filmdragerad tablett
bayer healthcare ag - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - laktosmonohydrat hjälpämne; moxifloxacinhydroklorid 436,8 mg aktiv substans - moxifloxacin
donepezil mylan 10 mg munsönderfallande tablett
mylan ab - donepezilhydroklorid, vattenfri - munsönderfallande tablett - 10 mg - donepezilhydroklorid, vattenfri 10 mg aktiv substans; mannitol hjälpämne - donepezil
donepezil mylan 5 mg munsönderfallande tablett
mylan ab - donepezilhydroklorid, vattenfri - munsönderfallande tablett - 5 mg - donepezilhydroklorid, vattenfri 5 mg aktiv substans; mannitol hjälpämne - donepezil
scemblix
novartis europharm limited - asciminib hydrochloride - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiska medel - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.